Abstract
BackgroundAlthough immune checkpoint inhibition has moved into the frontline setting for advanced and metastatic head and neck cancer (HNC), only a minority of patients experience durable treatment responses.1 Therapeutic resistance...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
